SCHEMBL16202076

SCHEMBL16202076

Cc1ccn(-c2cccc(Oc3ccccc3)c2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.46
RAB9A P51151 3/20 0.46
NPC1 O15118 2/20 0.46
ATM Q13315 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
MGLL Q99685 2/20 0.45
ALDH1A1 P00352 2/20 0.41
KDM4E B2RXH2 1/20 0.41
GAA P10253 1/20 0.41
GRM5 P41594 1/20 0.41
MAOB P27338 1/20 0.41
KAT6A Q92794 2/20 0.40
LMNA P02545 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
ESRRA P11474 1/20 0.40
NOTUM Q6P988 1/20 0.40
HTT P42858 1/20 0.40
HDAC4 P56524 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16202078 0.88 MAPT (0.41) MAPTRAB9ANPC1ATMSMN1; SMN2
SCHEMBL5963053 0.87 HTT (0.49) MAPTRAB9ANPC1ATMSMN1; SMN2
SCHEMBL24378467 0.83 NOTUM (0.57) MAPTRAB9ANPC1ATMSMN1; SMN2
SCHEMBL14412226 0.82 RAB9A (0.59) MAPTRAB9ANPC1ATMSMN1; SMN2
SCHEMBL541634 0.80 MAPT (0.55) MAPTRAB9ANPC1ATMSMN1; SMN2
SCHEMBL14277962 0.80 RAB9A (0.49) MAPTRAB9ANPC1ATMSMN1; SMN2
SCHEMBL5101204 0.78 MEN1 (0.56) MAPTRAB9ANPC1ATMSMN1; SMN2
SCHEMBL16202100 0.75 RAB9A (0.53) MAPTRAB9ANPC1ATMSMN1; SMN2
SCHEMBL7333158 0.75 MAPT (0.50) MAPTRAB9ANPC1ATMSMN1; SMN2
SCHEMBL122970 0.75 KEAP1 (0.53) MAPTRAB9ANPC1ATMSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160249615-A1 Use of Strobilurin Type Compounds for Combating Phytopathogenic Fungi Resistant to QO Inhibitors BASF SE (DE) 2016-09-01 US disclosed
US-20160145219-A1 STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI BASF SE (DE) 2016-05-26 US disclosed
US-20160145202-A1 Strobilurin Type Compounds for Combating Phytopathogenic Fungi BASF SE (DE) 2016-05-26 US disclosed
US-20160122327-A1 STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI BASF SE (DE) 2016-05-05 US disclosed
US-9271501-B2 Use of strobilurin type compounds for combating phytopathogenic fungi resistant to QO inhibitors BASF SE (DE) 2016-03-01 US disclosed
US-20140323305-A1 Use of Strobilurin Type Compounds for Combating Phytopathogenic Fungi Resistant to QO Inhibitors BASF SE (DE) 2014-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160122327-A1 STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI SNX1, DPM1, SNU13 MAPT 1798/4885RAB9A 2110/4885NPC1 634/4885
US-20160145219-A1 STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI DPM1, CROCC, SNX1 MAPT 1392/4885RAB9A 2327/4885NPC1 753/4885
US-20160145202-A1 Strobilurin Type Compounds for Combating Phytopathogenic Fungi DPM1, CROCC, SNX1 MAPT 1392/4885RAB9A 2327/4885NPC1 753/4885
US-20140323305-A1 Use of Strobilurin Type Compounds for Combating Phytopathogenic Fungi Resistant to QO Inhibitors SQOR, COX5B, UQCRB MAPT 2644/4885RAB9A 1342/4885NPC1 601/4885
US-20160249615-A1 Use of Strobilurin Type Compounds for Combating Phytopathogenic Fungi Resistant to QO Inhibitors SQOR, COX5B, UQCRB MAPT 2644/4885RAB9A 1342/4885NPC1 601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.